Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Comment: Pirtobrutinib improves PFS in treatment-naïve CLL/SLL compared to bendamustine/rituximab

ASH 2025

Published: 18 Dec 2025

Views: 8

Rating:

Save

Dr Tycel Phillips - City of Hope National Medical Center, Duarte, USA

Dr Tycell Phillips comments on the results of the Phase 3 BRUIN CLL-313 trial, comparing pirtobrutinib, a non-covalent BTKi, to bendamustine/rituximab in treatment-naïve chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL).

The study demonstrated a significant improvement in progression-free survival (PFS) with pirtobrutinib, low rates of treatment discontinuation, and a favorable safety profile, with a trend favoring overall survival despite high crossover to pirtobrutinib.

Click here to watch lead author Prof Wojciech Jurczak discuss this data.

Related Videos

Glofitamab, venetoclax, and lenalidomide combination shows promising efficacy...

Dr Tycel Phillips - City of Hope National Medical Center, Duarte, USA

Glofitamab, venetoclax, and lenalidomide combination shows promising efficacy in high-risk mantle cell lymphoma ( Dr Tycel Phillips - City of Hope National Medical Center, Duarte, USA )

Ropeginterferon alfa-2b is evaluated as a disease-modifying option in essential...

Prof Jean-Jacques Kiladjian - Hôpital Saint-Louis, Paris, France

Ropeginterferon alfa-2b is evaluated as a disease-modifying option in essential thrombocythemia ( Prof Jean-Jacques Kiladjian - Hôpital Saint-Louis, Paris, France )

Fixed-duration targeted treatment as effective as TKI Inhibitor therapy for CLL

Dr Othman Al-Sawaf - University Hospital of Cologne, Cologne, Germany

Fixed-duration targeted treatment as effective as TKI Inhibitor therapy for CLL ( Dr Othman Al-Sawaf - University Hospital of Cologne, Cologne, Germany )

Off-the-shelf in vivo CAR-T therapy KLN-1010 shows early MRD-negative responses...

Prof Joy Ho - Royal Prince Alfred Hospital, Sydney, Australia

$Off-the-shelf in vivo CAR-T therapy KLN-1010 shows early MRD-negative responses in relapsed/refractory multiple myeloma ( Prof Joy Ho - Royal Prince Alfred Hospital, Sydney, Australia )$

Anitocabtagene autoleucel achieves deep and durable responses in relapsed...

Dr Krina Patel - MD Anderson Cancer Center, Houston, USA

$Anitocabtagene autoleucel achieves deep and durable responses in relapsed/refractory multiple myelomas ( Dr Krina Patel - MD Anderson Cancer Center, Houston, USA )$

IP6K1-driven tumour polyphosphate may contribute to immune checkpoint inhibitor...

Dr Keith McCrae - Cleveland Clinic, Cleveland, USA

IP6K1-driven tumour polyphosphate may contribute to immune checkpoint inhibitor-associated thrombosis ( Dr Keith McCrae - Cleveland Clinic, Cleveland, USA )

New genomic map of adult B-ALL identifies CEBPalt subgroup and highlights...

Dr Xiaoming Zhong - St. Jude Children's Research Hospital, Memphis, USA

New genomic map of adult B-ALL identifies CEBPalt subgroup and highlights blinatumomab benefits in key high-risk molecular types ( Dr Xiaoming Zhong - St. Jude Children's Research Hospital, Memphis, USA )

Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant...

Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston...

Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients ( Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston, USA )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

More from ecancer